Skip to main content

Table 2 Summary of clinical approaches for inhibiting IL-6 activity in cancer

From: Tumor-related interleukins: old validated targets for new anti-cancer drug development

Class Drug Type Clinical trials Ref.
Monoclonal antibodies Tocilizumab Humanized anti-IL-6R mAb Cancer cachexia in lung cancer and phase I + II for multiple Myeloma [125]
Siltuximab Chimeric anti-IL-6 mAb Phase II multiple myeloma, phase I completed for B-cell non-Hodgkin’s lymphoma, multiple myeloma, phase II prostate cancer, phase II renal cell carcinoma, phase I oral mucositis in head and neck cancer and phase II non-small cell lung cancer-related cachexia [135]
Clazakizumab Humanized, aglycosylated anti-IL-6 mAb Multiple myeloma and phase II renal cell carcinoma [140]
Elsilimomab (BE-8)
Murine anti-IL-6 mAb
Chimeric anti–IL-6 mAb
Multiple Myeloma
Clinical trial for multiple myeloma, hormone-refractory prostate cancer, ovarian cancer, non-Hodgkin’s lymphoma, and renal cancer has been discontinued due to lack of efficacy
[138, 139]
Non-mAbs agents sgp130Fc Fc fusion gp130 IL-6 signaling blocker Preclinical studies [194]
SANT-7 IL-6R antagonist Combination therapy in multiple myeloma [195]
ERBA small molecule IL-6R
Cancer-related cachexia [196]
Atiprimod Small molecule JAK2 and JAK3 inhibitor Clinical trial in development for multiple myeloma [195]
Ruxolitinib Small molecule JAK1 and JAK2 inhibitor Phase II clinical trial for myeloproliferative neoplasms (MPN) and AML [146]